These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38710595)

  • 1. The Menin story in acute myeloid leukaemia-The road to success.
    Kühn MWM; Ganser A
    Br J Haematol; 2024 May; ():. PubMed ID: 38710595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
    Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
    Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the undruggable: menin inhibitors ante portas.
    Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.
    Candoni A; Coppola G
    Hematol Rep; 2024 Apr; 16(2):244-254. PubMed ID: 38651453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
    Kwon MC; Thuring JW; Querolle O; Dai X; Verhulst T; Pande V; Marien A; Goffin D; Wenge DV; Yue H; Cutler JA; Jin C; Perner F; Hogeling SM; Shaffer PL; Jacobs F; Vinken P; Cai W; Keersmaekers V; Eyassu F; Bhogal B; Verstraeten K; El Ashkar S; Perry JA; Jayaguru P; Barreyro L; Kuchnio A; Darville N; Krosky D; Urbanietz G; Verbist B; Edwards JP; Cowley GS; Kirkpatrick R; Steele R; Ferrante L; Guttke C; Daskalakis N; Pietsch EC; Wilson DM; Attar R; Elsayed Y; Fischer ES; Schuringa JJ; Armstrong SA; Packman K; Philippar U
    Blood; 2024 Sep; 144(11):1206-1220. PubMed ID: 38905635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
    Issa GC; Aldoss I; DiPersio J; Cuglievan B; Stone R; Arellano M; Thirman MJ; Patel MR; Dickens DS; Shenoy S; Shukla N; Kantarjian H; Armstrong SA; Perner F; Perry JA; Rosen G; Bagley RG; Meyers ML; Ordentlich P; Gu Y; Kumar V; Smith S; McGeehan GM; Stein EM
    Nature; 2023 Mar; 615(7954):920-924. PubMed ID: 36922593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?
    Swaminathan M; Bourgeois W; Armstrong SA; Wang ES
    Cancer J; 2022 Jan-Feb 01; 28(1):62-66. PubMed ID: 35072375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
    Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
    Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.
    Thomas X
    Oncol Ther; 2024 Mar; 12(1):57-72. PubMed ID: 38300432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revumenib for patients with acute leukemia: a new tool for differentiation therapy.
    Salman MY; Stein EM
    Haematologica; 2024 Aug; ():. PubMed ID: 39086307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
    Jen WY; Kantarjian H; Kadia TM; DiNardo CD; Issa GC; Short NJ; Yilmaz M; Borthakur G; Ravandi F; Daver NG
    Br J Haematol; 2024 Jul; 205(1):30-47. PubMed ID: 38724457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic implications of menin inhibition in acute leukemias.
    Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
    Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
    Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
    Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
    Brivio E; Baruchel A; Beishuizen A; Bourquin JP; Brown PA; Cooper T; Gore L; Kolb EA; Locatelli F; Maude SL; Mussai FJ; Vormoor-Bürger B; Vormoor J; von Stackelberg A; Zwaan CM
    Eur J Cancer; 2022 Mar; 164():1-17. PubMed ID: 35121370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MLL-Menin Interaction is a Therapeutic Vulnerability in
    Rasouli M; Blair H; Troester S; Szoltysek K; Cameron R; Ashtiani M; Krippner-Heidenreich A; Grebien F; McGeehan G; Zwaan CM; Heidenreich O
    Hemasphere; 2023 Aug; 7(8):e935. PubMed ID: 37520776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
    Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
    Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.